Accelerating Development of Therapeutics to Bolster Global Protein Supply Chains
Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
Canary Speech announces it has obtained HITRUST e1 Certification, reinforcing its commitment to cybersecurity related to its voice biomarker technology.
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval.
GE HealthCare’s Economic Impact Across Utah
RefloDx Wins Trans Atlantic Angel Grand Prize.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.